Effect of Botulinum Toxin in the Treatment of Drooling: A Controlled Clinical Trial

Peter H. Jongerius, Frank J.A. van den Hoogen, Jacques van Limbeek, Fons J. Gabreëls, Karen van Hulst and Jan J. Rotteveel

Pediatrics 2004;114;620
DOI: 10.1542/peds.2003-1104-L

The online version of this article, along with updated information and services, is located on the World Wide Web at:

http://pediatrics.aappublications.org/content/114/3/620.full.html
Effect of Botulinum Toxin in the Treatment of Drooling: A Controlled Clinical Trial

Peter H. Jongerius, MD*; Frank J.A. van den Hoogen, MD, PhD‡; Jacques van Limbeek, MD, PhD§; Fons J. Gabreëls, MD, PhD*; Karen van Hulst, BSc¶; and Jan J. Rotteveel, MD, PhD||

ABSTRACT. Objective. To investigate the clinical effectiveness of botulinum neurotoxin type A (BoNT) to reduce drooling in children with cerebral palsy (CP).

Methods. A controlled clinical trial was performed in which the results of single-dose BoNT injections in the submandibular glands were compared with treatment with scopolamine. Forty-five children who had CP and experienced severe drooling were enrolled. Drooling severity was measured at baseline, during application of scopolamine, and at different intervals after BoNT injections up to 24 weeks, using the Drooling Quotient (DQ), the Teacher Drooling Scale (TDS), and Visual Analog Scales (VAS).

Results. Drooling was reduced during scopolamine application as well as after BoNT injections. Compared with baseline, the mean DQ showed a significant decrease throughout the study. Greatest reductions were achieved 2 to 8 weeks after BoNT injection. No significant differences were found between scopolamine measurements and those up to 24 months after BoNT injection. Using VAS, parents recorded the effect on drooling in which significant differences were found between baseline VAS score and all follow-up assessments. According to our definition of “success to therapy,” demanding a 2-point decrease on the TDS, 61.5% of patients responded to BoNT injections. Analysis of the DQ demonstrated a response rate of 53% of the patients to scopolamine and 48.7% to BoNT until 24 weeks after BoNT injection, the actual duration of this study. As a reaction to scopolamine, 71.1% of the patients had moderate to severe side effects. Only nonsevere, incidental side effects were reported after BoNT injections.

Conclusions. During scopolamine application as well as after intraglandular BoNT injections, a clinically relevant reduction in drooling was achieved in children with CP, demonstrating maximum effect 2 to 8 weeks after injections. This is the first controlled clinical trial that confirmed a significant effect of BoNT injections in the treatment of drooling. General anesthesia was needed for all children. BoNT injections show fewer and less serious side effects than transdermal scopolamine treatment.
dures all have their limitations.22 Recent reports suggested botulinum neurotoxin type A (BoNT) injections into the salivary glands as an option for treatment of drooling.6,9,10 These reports are case series and small cohort studies that lack the power to prove the efficacy of BoNT injections. Ellies et al23 studied a larger population and concluded that the BoNT effect lasted for ~2 to 3 months. From the pharmacologic profile of BoNT, an appreciable anticholinergic effect can be expected. In particular, type A toxin cleaves SNAP-25, an enzyme involved in the release of acetylcholine at the presynaptic membrane of parasympathetic nerves. In this way, a temporary denervation of the target organ is established. Botulinum toxin is known to give clinically relevant results for 9 to 12 months in other conditions involving the autonomic nervous system, for example hyperhidrosis.24,25 Although BoNT has been suggested for clinical use in the treatment of drooling, uncertainty remains about the clinical effect and duration.

In this study, a controlled clinical trial on the treatment of drooling was performed in which BoNT injections in the submandibular glands were compared with scopolamine treatment. Difference scores of semiquantitative measurements of drooling (DQ, TDS, Visual Analog Scales [VAS]) were analyzed. The null hypothesis that the effect on drooling would not differ between scopolamine and BoNT was tested.

**METHODS**

Forty-five children with the diagnosis CP were recruited from the outpatient clinic and enrolled in the study between January 2000 and November 2001. Consecutive patients were included during a qualification period in which inclusion criteria and exclusion criteria were examined (Table 1).

A score of 3 or higher on the TDS (Table 2) was mandatory to be included in the study.15 All drugs used were evaluated carefully to assess their influence on saliva secretion. Drugs to treat drooling had to be stopped at least 3 months before participation. Throughout the study, no medication that could influence the severity of drooling was allowed. No requirements were set with regard to the child’s level of mental development.

Possible adverse effects and risks related to the interventions

**TABLE 1. Inclusion and Exclusion Criteria**

<table>
<thead>
<tr>
<th>Inclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Children (male and female) of preschool and school age (subjects aged 3–18 y)</td>
</tr>
<tr>
<td>Diagnosis of CP</td>
</tr>
<tr>
<td>A score of ≥3 on the TDS, indicating severe drooling</td>
</tr>
<tr>
<td>All medication, taken to treat drooling, stopped at least 3 mo before start of the study</td>
</tr>
<tr>
<td>Minimal body weight 8 kg</td>
</tr>
<tr>
<td>Informed consent obtained</td>
</tr>
<tr>
<td>Caregivers have high enough cognitive ability to participate in the study</td>
</tr>
<tr>
<td>Readiness to participate for ~8 mo</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Exclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Child is enrolled in another medical study</td>
</tr>
<tr>
<td>Previous surgical procedures in the oral/nasal cavity</td>
</tr>
<tr>
<td>Interfering with saliva production</td>
</tr>
<tr>
<td>Treatment with BoNT for another indication in the previous 6 mo</td>
</tr>
<tr>
<td>Known hypersensitivity to Botox or any part of the formulation</td>
</tr>
<tr>
<td>Use of drugs that interfere with saliva secretion</td>
</tr>
<tr>
<td>Known systemic diseases (bronchial asthma, congenital heart failure, and myasthenia gravis)</td>
</tr>
</tbody>
</table>

**TABLE 2. TDS**

<table>
<thead>
<tr>
<th>Score</th>
<th>Drooling</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>No drooling</td>
</tr>
<tr>
<td>2</td>
<td>Infrequent drooling; small amount</td>
</tr>
<tr>
<td>3</td>
<td>Occasional drooling; intermittent all day</td>
</tr>
<tr>
<td>4</td>
<td>Frequent drooling but not profuse</td>
</tr>
<tr>
<td>5</td>
<td>Constant drooling; always wet</td>
</tr>
</tbody>
</table>

**Study Design**

The study was executed as a controlled, open-label, clinical trial. The difference between the 2 episodes of treatment had to be at least 0.7 SD. Drooling evaluation (see Procedures) was performed during baseline, scopolamine application, and after BoNT injections into the submandibular glands. The sequence of interventions had a fixed order: scopolamine before BoNT. This was chosen because the washout period of scopolamine is known, whereas the duration of the supposed effect of BoNT needed to be determined. An independent employee assessed the primary outcome parameters blinded for the status of the participating patients, which was achieved by varying the number of baseline measurements among the patients according to a predetermined schedule.

In view of side effects of scopolamine, the protocol anticipated that some of the patients might not complete the scopolamine period. When scopolamine was used for <48 hours, the patient was considered a dropout. When scopolamine was discontinued >48 hours after start, the patient remained in the study, provided that a control measurement was obtained within the first 24 hours after discontinuation of the therapy. Patients returned for follow-up measurements at 2, 4, 8, 16, and 24 weeks after BoNT injections. Patients had to have undergone at least 1 of the scheduled investigations at 2, 4, or 8 weeks. At least 3 of 5 visits within the first 24 weeks after BoNT injections had to be conducted.

If a patient was excluded during the use of scopolamine or during the washout period, it was planned to contact the parents by telephone after 2 and 4 weeks to check for adverse effects or other complaints. Dropouts after the BoNT injections were to be contacted monthly until 24 weeks after injection.

**Procedures**

A scopolamine patch (Scopo-derm TTS; Novartis Consumer Health BV, Breda, Netherlands) was placed behind the ear and changed within every 72 hours. An assessment was scheduled on the 10th day, with the 4th plaster in situ being applied no longer than 48 hours before. After a washout period of 2 to 4 weeks, the child was admitted for outpatient treatment. Using general anesthesia for all patients, a single dose of botulinum toxin (Botox; Allergan, Nieuwegein, Netherlands), reconstituted with 0.9% sodium chloride solution, was injected bilaterally in the submandibular glands using a 25-G needle (Spinocan) and a 1-mL syringe. Weight-dependent dosages were injected in each gland: 15 U/gland for children who weighed <15 kg, 20 U/gland for children with a body weight of between 15 kg and 25 kg, and 25 U/gland for children who weighed >25 kg. On injection, each dose was fractionated and divided over minimally 3 sites in the gland. Ultrasound guidance was performed using a system (SAL 250; Toshiba Medical Systems Corporation, Tokyo, Japan) equipped with a 7.5-MHz transducer. Only the submandibular glands were injected. It is generally accepted that these glands produce 60% to 70% of secreted resting saliva when the individual is not eating or drinking.26 Saliva that is produced during eating and drinking is produced mainly by the parotid glands, with which we did not want to interfere. The sublingual glands, contributing up to 5% to the total saliva production, were not treated. After BoNT, parents were asked to register all possible side effects in a diary. These were discussed during outpatient visits.

**Assessment of Drooling**

The DQ and VAS served as the primary outcome measures for this study. The TDS, scored on an ordinal scale, was used to give supportive evidence for the efficacy of BoNT.
The DQ was scored according to its original design during 2 periods of 10 minutes separated by a 60-minute break. An episode of drooling was defined as new saliva present on the lip margin or dropping from the chin. Every 15 seconds (40 observations in 10 minutes), the presence or absence of drooling was assessed. Patients were evaluated at least 1 hour after a meal while awake and sitting erect. Two speech therapists were especially trained to execute the measurements. Separate observations were made during different activities: 1) with the child watching television and 1 during an activity, as chosen by the child, that demanded a higher level of concentration or physical effort. The mean of the 2 observations was used for analysis to provide an outcome on a numeric scale.

The DQ was expressed as a percentage estimated from the ratio of observed drooling episodes and the total number of observations (DQ [%] = 100 × number of drooling episodes/40). DQ assessments were made at baseline, during the use of scopolamine, at washout after ending scopolamine therapy, and at regular intervals after BoNT injections (2, 4, 8, 16, and 24 weeks).

After receiving specific instructions, parents filled out VAS to investigate therapy results as experienced in the home situation. Scales of exactly 10 cm without visible subdivisions were presented on which the average degree of drooling severity during the 10 to 14 days before assessment had to be indicated. A mark at the left end represented severe drooling; a mark at the right end meant no drooling. An independent employee scored the VAS with a ruler in millimeters, resulting in a number ranging from 0 to 100, which was handled as a parametric variable. VAS assessment was made at baseline, during the use of scopolamine, and at regular intervals after BoNT injections (4, 8, 16, and 24 weeks). The TDS (Table 2) was used to assess the degree of drooling by interviewing the parents or caregivers during outpatient visits. Assessments of TDS were made at baseline and after BoNT injections (8 and 24 weeks). Before analysis of the data, a significant reaction to therapy was defined as a 2-point improvement on the TDS (range: 1–5; Table 2). The outcome after BoNT injections is used only to support the findings in the DQ and VAS data.

Statistics

A power analysis was performed before start of the study. Approximately 40 patients were needed to reach a power of 80% with an \( \alpha \) of .05. The difference between the 2 episodes of treatment had to be at least 1 SD. Assuming a dropout percentage of 7%, the inclusion of 45 patients was sufficient. Because of the complexity of the design and vulnerability of the patients, missing data were inevitable. For this reason, data were adjusted in 2 ways: 1) by carrying the last observation forward data. Descriptive statistics of the consecutive measurement moments showed that, compared with baseline, the mean DQ decreased during scopolamine application as well as after BoNT injections, which is shown in Fig 1. With the DQ at each moment in time defined as the within-subjects variable, a MANOVA with a repeated measurements design was executed to evaluating a bias toward the null. The outcomes of both approaches were compared.

All statistical procedures were conducted with SPSS/pc+ (version 9.0; SPSS, Inc, Chicago, IL). Data analysis included descriptive statistics; multivariate analysis of variance (MANOVA) of repeated measurements to identify patterns of response over time, using a within-subjects design with the measurement moments as the variables; and paired-samples \( t \) tests to analyze differences of paired observations (DQ and VAS) at subsequent measurements. In addition, success of therapy for either scopolamine or BoNT was defined as a decrease in DQ of at least 50% of the patient’s baseline value. Frequency analyses were performed to determine the percentage of responders in the population. A Wilcoxon signed ranks test was used to analyze changes in TDS (ordinal scale). For all statistics, a level of significance with a 1-sided \( P \leq .05 \) was mandatory.

RESULTS

Forty-five children were included: 28 boys and 17 girls (age: 3–17 years; mean: 9.5; SD: 3.7). Eight were ambulant without aid, 37 had wheelchairs, 22 could not talk, 29 attended a special education school, and 14 went to a child care center for mentally handicapped children. Thirty-four children had mental retardation with a developmental level <6 years as determined by psychological investigation.

None of the patients was treated with botulinum toxin before. By the end of the trial, 6 dropouts had occurred: 4 patients could not fulfill the scopolamine period, 1 changed antiepileptic medication, and 1 did not attend the required measurements because of an intercurrent illness not related to the trial. The results of 39 patients could be analyzed.

DQ

In the first instance, analyses were executed with carrying the last observation forward data. Descriptive statistics of the consecutive measurement moments showed that, compared with baseline, the mean DQ decreased during scopolamine application as well as after BoNT injections, which is shown in Fig 1. With the DQ at each moment in time defined as the within-subjects variable, a MANOVA with a repeated measurements design was executed to eval-

![Fig 1. DQ: mean in time. Sc indicates application of Scopolamine; BTX, injection of botulinum toxin.](image-url)
evaluate the pattern of response during the trial (Hotelling’s trace: $F = 12.79$; $df [7,00]; P = .000$). An effect over time was found as depicted in Fig 1 and described in additional detail by analysis of difference.

Univariate analyses were executed to analyze further interval difference scores. To justify the length of the washout period, we compared the DQ values at the interval difference scores. To justify the length of the washout period, we compared the DQ values at the interval difference scores. To justify the length of the washout period, we compared the DQ values at baseline with the measurements after washout of scopolamine, using a paired-samples $t$ test. The mean change in DQ from baseline to washout value was estimated to be $-1.60$, which was a nonsignificant difference ($t = -0.464; df [38]; P = .32, 1 tailed$). This finding minimizes the probability of a carryover effect from scopolamine treatment to BoNT, indicating that the length of washout after scopolamine application was sufficient.

Changes in DQ (expressed as differences), SD, and $P$ values between baseline and the subsequent measurements are tabulated in Table 3. All DQ measurements showed a significant decrease (mean differences: $15.5–21.7$; $P \leq .05$, based on paired samples $t$ tests).

The greatest reduction was achieved 2 weeks after BoNT injections (BoNT-2: mean difference score: $21.7$; SD: $18.3; P = .000$). The DQ increased slightly after BoNT-2. At the end of the study, though, a significant reduction of drooling was still found, suggesting an ongoing effect.

During additional analysis, scopolamine measurements were compared with the measurements after BoNT injections up to 24 weeks (Table 4). No significant differences were found (mean differences: $-2.2$ to $4.1; P > .05$, based on paired samples $t$ tests). Analysis of WCS data did not lead to different results comparing baseline with both treatments.

According to our definition of success to therapy, patients could be assigned as a responder when baseline DQ decreased by $50\%$ or more during the interventions. Analysis of frequencies was done. During scopolamine, $53\%$ of the patients were recognized as responders. Response rates to BoNT were as follows: BoNT-2, $64.1\%$; BoNT-4, $43.5\%$; BoNT-8, $53\%$; BoNT-16, $41\%$; and BoNT-24, $48.7\%$.

**TABLE 3.** Mean Differences Between Baseline and Follow-up Measurements

<table>
<thead>
<tr>
<th>Pairs of Observation</th>
<th>DQ Difference (SD)</th>
<th>Significance*</th>
<th>VAS Difference (SD)</th>
<th>Significance*</th>
</tr>
</thead>
<tbody>
<tr>
<td>BI/scopolamine</td>
<td>17.7 (21.2)</td>
<td>.000</td>
<td>-34.3 (30.9)</td>
<td>.000</td>
</tr>
<tr>
<td>BI/BoNT-2</td>
<td>21.7 (18.3)</td>
<td>.000</td>
<td>-30.1 (22.8)</td>
<td>.000</td>
</tr>
<tr>
<td>BI/BoNT-4</td>
<td>16.1 (18.9)</td>
<td>.000</td>
<td>-22.1 (23.9)</td>
<td>.000</td>
</tr>
<tr>
<td>BI/BoNT-8</td>
<td>20.0 (20.5)</td>
<td>.000</td>
<td>-20.5 (24.9)</td>
<td>.000</td>
</tr>
<tr>
<td>BI/BoNT-16</td>
<td>15.5 (19.1)</td>
<td>.000</td>
<td>-13.5 (25.7)</td>
<td>.002</td>
</tr>
<tr>
<td>BI/BoNT-24</td>
<td>15.7 (16.4)</td>
<td>.000</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

BI indicates baseline.

* Paired-samples $t$ tests, 1-sided $P < .05$.

The analysis of the VAS showed an effect over time. The Wilcoxon signed ranks test was used to analyze changes in TDS over time. Compared with baseline, a significant decrease was observed at BoNT-8 ($Z = -4.8; P = .000, 1-tailed$) and BoNT-24 ($Z = -4.1; P = .000, 1-tailed$). The TDS is an ordinal scale; as such, the outcome can provide only supportive evidence. To confirm the outcome, the TDS should show changes in the same direction as the VAS (Fig 3). The curve shows that at baseline, all patients were severely drooling (mean: $4.9$). Drooling diminished after BoNT injections. At BoNT-8, the mean score decreased to $3$, indicating occasional drooling. At BoNT-24, the mean TDS score equaled $3.8$.

The TDS was also used to define success to therapy (see Methods). An analysis of frequency of scores on the TDS was made to provide insight into parents’ recognition of the BoNT therapy effect. Eight weeks after the BoNT injections, TDS scores were as follows: $1$, $15.4\%$; $2$, $28.2\%$; and $3$, $17.9\%$. This indicates that $61.5\%$ of the patients were good responders according to our definition; $15.4\%$ of the children had to score $3$ or higher on the TDS to be included in the study. At start of the study, $94.9\%$ of the patients had a score of $5$, with the remaining $5.1\%$ having a score of $4$. A success to therapy was defined as a $2$-point improvement on the TDS (see Methods). The Wilcoxon signed ranks test was used to analyze changes in TDS over time. Compared with baseline, a significant decrease was observed at BoNT-8 ($Z = -4.8; P = .000, 1-tailed$) and BoNT-24 ($Z = -4.1; P = .000, 1-tailed$). The TDS is an ordinal scale; as such, the outcome can provide only supportive evidence. To confirm the outcome, the TDS should show changes in the same direction as the VAS (Fig 3). The curve shows that at baseline, all patients were severely drooling (mean: $4.9$). Drooling diminished after BoNT injections. At BoNT-8, the mean score decreased to $3$, indicating occasional drooling. At BoNT-24, the mean TDS score equaled $3.8$.
changed only slightly (score: 4). Twenty-three percent of the cases, representing 9 patients, did not show improvement compared with their initial score. Eight (20.5%) patients remained at score 5, and 1 (2.5%) patient remained at score 4. None of the parents reported an increase in drooling severity as a result of therapy.

None of the patients showed improvement between BoNT-8 and BoNT-24. TDS frequency scores at BoNT-24 were as follows: 1, 5.1%; 2, 15.4%; 3,
every day; 3

Side Effects

Parents scored the extent of side effects on a 4-point scale (0 = no side effect; 1 = mild, not every day/occurring sometimes; 2 = moderate, present every day; 3 = severe side effect, constantly present). Side effects as a result of scopolamine became apparent within the first 3 days of administration, and several patients complained of >1 symptom. Adverse effects during application of scopolamine were reported in 82.2% of cases. Five (11.1%) patients had mild, 14 (31.1%) patients had moderate, and 18 (40%) patients had severe side effects.

Most often reported adverse effects were xerostomia (66.7%), restlessness (35.6%), somnolence (35.6%), blurred vision because of pupillary dilation, and confusion (20%). Four of the 6 dropouts from the study had to end their participation because of adverse effects to scopolamine. In all 4 cases, restlessness, apparent in their movement performance, and confusion were the main reasons to terminate scopolamine use. After BoNT injections, incidental side effects were reported. Two (5.1%) patients had a transient flu-like syndrome that lasted for <2 days. Another 3 patients complained of mild difficulty with swallowing.

DISCUSSION

This is the first controlled, clinical trial to evaluate the treatment of drooling in children with CP by comparing the efficacy of 2 different anticholinergic agents: bilateral single-dose BoNT injections into the submandibular glands and transdermal scopolamine. A positive clinical effect from intraglandular BoNT injections as well as scopolamine application was found. Scopolamine was expected to have a larger part of resting saliva. In addition, it underlines that BoNT has a strong anticholinergic effect in the target glands.

The outcomes of clinically relevant parameters (DQ and VAS) were in accordance with each other, showing a reduction in drooling after both interventions. The parents’ reports about their child’s drooling at home (VAS scores) showed significant change. A similar positive effect was demonstrated in the reduction of DQ after BoNT injections up to 24 weeks, the end of the study. Response rates, as analyzed in the DQ data, were high. Of all patients, 53% responded during scopolamine, 64.1% responded 2 weeks after BoNT injections, and 53% responded 8 weeks after injections. After 24 weeks, 48.7% of the patients still responded to BoNT. Success to therapy was also defined as a 2-point decrease of the TDS as compared with baseline. Eight weeks after BoNT injections, 61.5% of the patients could be registered as responders according to the TDS approach. At the end of the study (BoNT-24), 35.9% of the patients were still responding to the BoNT injections.

The outcome of success to therapy as described with the DQ is based on an objective observation expressed on a numeric scale. The result of the TDS is a subjective expression on an ordinal scale. Still, the results of both observations on BoNT are congruent. Comparable outcomes on drooling in BoNT studies have been reported in observational studies.

Transdermally applied scopolamine and oral anticholinergic agents such as glycopyrrolate and benzotropine have been widely investigated in the treatment of drooling. Lewis et al31 randomly assigned patients to a 2-week use of scopolamine patches and placebo patches using a crossover design. Success to therapy was recorded in 80% of patients. Blasco and Stansbury28 performed a prospective open-label study in which 90% of the patients had reduced drooling in response to glycopyrrolate, based on the subjective reports by parents. Bachrach et al27 investigated the results of glycopyrrolate among 37 patients in a questionnaire-based cohort study. Parents were asked to describe the amount of drooling before medication had begun and while their child was taking the medication, using a 5-point scale. A significant improvement was present in 95% of cases. Mier et al32 used increasing dosages of glycopyrrolate in a placebo-controlled clinical trial. According to their definition of success to therapy, 81% of patients responded to the highest dosage. The above-mentioned success rates all exceeded the 53% responders found in the present study. An explanation for this difference could be that the definitions of response (a 50% reduction or more of the DQ, in our study) used in the studies are not interchangeable.

Disadvantages of systemic anticholinergic drugs are the many side effects. Severe side effects were observed in 40% of cases. Symptoms such as xerostomia, restlessness, somnolence, blurred vision, and confusion were apparent in this study, necessitating ending the therapy in 7% of the participants. In this way, 4 of 6 dropouts were attributed to scopolamine. It was theorized that side effects are probably even underscored in this study population, taking into account the patients’ inability to present their complaints clearly. Besides, scopolamine was applied for a relatively short period. Thus, continued use of scopolamine in a dosage large enough to treat severe drooling seems undesirable.

Side effects as a result of anticholinergic therapy are also described in other studies. Lewis et al31 reported two third of his population to have papillary dilatation, and ~27% demonstrated pruritus or increased mouthing behavior as a reaction to scopolamine. Applying glycopyrrolate, 32.5% of the pa-
patients had adverse effects of which behavioral changes (13%) were specified in a percentage. Mier et al. reported that adverse effects were common, affecting 69% of the children who took glycopyrrolate. The identified side effects ranged from 10% to 23%, comprising behavioral changes, facial flushing, nasal congestion, constipation, vomiting, diarrhea, dry mouth, urinary retention, and blurred vision. Seven of 36 participants withdrew from the study because of side effects. Although side effects seem to be common in relation to the use of anticholinergic drugs, the intensity and the occurrence of central effect may vary, depending on the drug of choice.

BoNT led to temporary complaints about swallowing in 2 cases. This was ascribed to local swelling in 1 patient. In another case, moderate difficulty with swallowing developed after 1 week and remained for 10 days. It was theorized that this might have been the result of diffusion of BoNT into the surrounding muscles. Other authors explicitly noted that no side effect were seen after BoNT injections.

BoNT, when accidentally injected next to the salivary glands, will influence neural activity at the neuromuscular junction as well. To avoid side effects and achieve optimal results, ultrasound guidance is strongly recommended. Although easy to perform, BoNT injections are to some extent invasive. General anesthesia could be regarded as a disadvantage. In this respect, it must be emphasized that other authors performed the procedure without anesthesia.

As chosen in our protocol, only the submandibular glands were treated. However, it must be realized that there may exist indications to treat the parotids as well, for example, excessive drooling during eating and drinking.

To our knowledge, this is the first controlled clinical trial in the treatment of drooling, evaluating the effect of scopolamine application and intraglandular BoNT injections into the submandibular glands. Both treatments significantly reduced drooling compared with baseline. The outcome of both therapies is in the same range and, no significant differences were found between DQ measurements during scopolamine and BoNT. A disadvantage in the treatment with scopolamine is the high percentage of observed adverse reactions, whereas BoNT injections need general anesthesia in children. The BoNT effect is temporary, although longer duration might be expected especially after recurrent treatment because of supposed hypotrophy of the glands after long denervation. Referring to the demands about the diagnosis and TDS, as stated in the inclusion criteria, the generalizability of this study is limited to comparable groups of patients. Additional research is needed to investigate BoNT therapy in other groups and to compare it with other interventions to treat drooling, such as surgery. Considering the social burden to the affected children, it is relevant to develop clinical guidelines to distinguish types and age groups of drooling patients to optimize the treatment modalities that are specifically effective.

In conclusion, during scopolamine application and after intraglandular BoNT injections, a clinically relevant reduction of drooling was achieved in children with CP, demonstrating maximum effect 2 to 8 weeks after injections. Analysis of the DQ demonstrated a response rate to scopolamine of 53% and of nearly 50% until 24 weeks after BoNT injections, the actual duration of this study. Additional research is warranted to optimize selection of patients in an effort to maximize the therapeutic effect.

ACKNOWLEDGMENTS

This work was supported by a grant from the Johanna Kinder-Fonds (Arnhem, Netherlands), a fundraising consortium in the field of child rehabilitation.

We express our gratitude to Frank Joosten, MD, PhD, and Lia van Die, MD, radiologists, and Ricky van der Heijden, trial monitor, for essential professional contributions to the study.

REFERENCES


34. Siegel LK, Klingbeil MA. Control of drooling with transdermal scopolamine in a child with cerebral palsy. Dev Med Child Neurol. 1991;33:1013–1014


BLAME LIFESTYLE FOR MYOPIA EPIDEMIC?

“Contrary to popular belief, people in East Asia are no more genetically susceptible to short-sightedness than any other population group, according to researchers who have analyzed the past studies of the problem. The epidemics of myopia in countries such as Singapore and Japan are due solely to changes in lifestyle, they say, and similar levels could soon be seen in many western countries as lifestyles there continue to change. ‘As kids spend more time indoors on computers or watching telly, we are going to become just as myopic,’ says Ian Morgan of the Australian National University in Canberra. Myopia is on the increase in most places, but in countries such as Singapore it has reached extraordinary levels. There, 80 percent of 18-year-old male army recruits are myopic, up from 25 percent just 30 years ago. . . Another study found myopia rates of 80 percent in 14- to 18-year-old boys studying in schools in Israel that emphasize reading religious texts. The rate for boys in state schools was just 30 per cent. . . In Sweden, for instance, 50 percent of children aged 12 now have myopia. It is expected that when these children reach 18 the rate will be more than 70 percent.”

Nowak R. New Scientist. July 10, 2004

Noted by JFL, MD
Effect of Botulinum Toxin in the Treatment of Drooling: A Controlled Clinical Trial

Peter H. Jongerius, Frank J.A. van den Hoogen, Jacques van Limbeek, Fons J. Gabreëls, Karen van Hulst and Jan J. Rotteveel

Pediatrics 2004;114;620
DOI: 10.1542/peds.2003-1104-L

Updated Information & Services
including high resolution figures, can be found at:
http://pediatrics.aappublications.org/content/114/3/620.full.html

References
This article cites 35 articles, 4 of which can be accessed free at:
http://pediatrics.aappublications.org/content/114/3/620.full.html#ref-list-1

Citations
This article has been cited by 11 HighWire-hosted articles:
http://pediatrics.aappublications.org/content/114/3/620.full.html#related-urls

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://pediatrics.aappublications.org/site/misc/Permissions.xhtml

Reprints
Information about ordering reprints can be found online:
http://pediatrics.aappublications.org/site/misc/reprints.xhtml

PEDIATRICS is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since 1948. PEDIATRICS is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 2004 by the American Academy of Pediatrics. All rights reserved. Print ISSN: 0031-4005. Online ISSN: 1098-4275.